XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Shareholders’ equity
 6 Months Ended
Jun. 30, 2025
Stockholders' Equity Note [Abstract]  
Shareholders’ equity Shareholders’ equity
Authorized share capital
The Company’s authorized share capital consists of an unlimited number of common shares and preferred shares, without par value, and 1,164,000 Series A participating convertible preferred shares, without par value.
Open Market Sale Agreement

Effective March 26, 2025, the Company terminated its Open Market Sale Agreement with Jefferies LLC (Jefferies) dated December 20, 2018, as amended (the Sale Agreement), under which the Company could offer and sell common shares, from time to time.

Prior to the termination of the Sale Agreement, the Company did not issue any common shares pursuant to the Sale Agreement during the six months ended June 30, 2025. During the three and six months ended June 30, 2024, the Company issued 7,833,922 and 16,499,999 common shares pursuant to the Sale Agreement, respectively, resulting in net proceeds of $22.4 million and $44.1 million, respectively.
Stock-based compensation

The table below summarizes information about the Company’s stock-based compensation for the three and six months ended June 30, 2025 and 2024 and the expense recognized in the condensed consolidated statements of operations:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in thousands, except share and per share data)
Stock options
Options granted during period762,400 424,200 4,706,122 4,163,000 
Weighted average exercise price$3.34 $3.27 $3.32 $2.49 
Restricted stock units (RSUs)
Restricted stock units granted during period— — 901,900 1,316,200 
Grant date fair value$— $— $3.29 $2.40 
Stock compensation expense
Research and development$374 $1,119 $929 $2,160 
General and administrative390 2,061 1,128 3,034 
Total stock compensation expense$764 $3,180 $2,057 $5,194